News Focus
News Focus
Replies to #97809 on Biotech Values
icon url

genisi

06/24/10 2:28 AM

#97821 RE: DewDiligence #97809

This must be bad news for anti-NGF mAb programs. SNY/REGN have an anti-NGF mAb in phase II for osteoarthritis pain.